202 related articles for article (PubMed ID: 9305902)
41. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
[TBL] [Abstract][Full Text] [Related]
42. Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.
Demers SI; Phaneuf D; Tanguay RM
Am J Hum Genet; 1994 Aug; 55(2):327-33. PubMed ID: 7913582
[TBL] [Abstract][Full Text] [Related]
43. Gene expression profiles of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays.
Tanaka Y; Nakamura K; Matsumoto S; Kimoto Y; Tanoue A; Tsujimoto G; Endo F
Mol Genet Metab; 2006 Nov; 89(3):203-9. PubMed ID: 16899383
[TBL] [Abstract][Full Text] [Related]
44. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
45. Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient
Yang H; Rossignol F; Cyr D; Laframboise R; Wang SP; Soucy JF; Berthier MT; Giguère Y; Waters PJ; Mitchell GA;
Mol Genet Metab Rep; 2018 Mar; 14():55-58. PubMed ID: 29326876
[TBL] [Abstract][Full Text] [Related]
46. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
47. Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III.
Rüetschi U; Cerone R; Pérez-Cerda C; Schiaffino MC; Standing S; Ugarte M; Holme E
Hum Genet; 2000 Jun; 106(6):654-62. PubMed ID: 10942115
[TBL] [Abstract][Full Text] [Related]
48. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
[TBL] [Abstract][Full Text] [Related]
49. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.
Labelle Y; Puymirat J; Tanguay RM
Biochim Biophys Acta; 1993 Jan; 1180(3):250-6. PubMed ID: 8422430
[TBL] [Abstract][Full Text] [Related]
50. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Nicole LM; Valet JP; Laberge C; Tanguay RM
Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
[TBL] [Abstract][Full Text] [Related]
51. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
52. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
[TBL] [Abstract][Full Text] [Related]
53. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
Overturf K; Al-Dhalimy M; Tanguay R; Brantly M; Ou CN; Finegold M; Grompe M
Nat Genet; 1996 Mar; 12(3):266-73. PubMed ID: 8589717
[TBL] [Abstract][Full Text] [Related]
54. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
[TBL] [Abstract][Full Text] [Related]
55. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
56. Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism.
Fernández-Cañón JM; Baetscher MW; Finegold M; Burlingame T; Gibson KM; Grompe M
Mol Cell Biol; 2002 Jul; 22(13):4943-51. PubMed ID: 12052898
[TBL] [Abstract][Full Text] [Related]
57. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
[TBL] [Abstract][Full Text] [Related]
58. Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I.
Pérez-Carro R; Sánchez-Alcudia R; Pérez B; Navarrete R; Pérez-Cerdá C; Ugarte M; Desviat LR
Clin Genet; 2014 Aug; 86(2):167-71. PubMed ID: 23895425
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
